Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a consensus rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.16.
SNSS has been the subject of several recent analyst reports. Oppenheimer initiated coverage on Sunesis Pharmaceuticals in a research note on Thursday, December 14th. They set a “buy” rating and a $7.00 target price for the company. Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Thursday, November 2nd. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Cantor Fitzgerald restated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Wednesday, September 27th. Finally, Wells Fargo & Co downgraded Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $2.70 to $2.00 in a research report on Tuesday, December 5th.
In other news, major shareholder Mpm Oncology Impact Management acquired 25,300 shares of Sunesis Pharmaceuticals stock in a transaction on Thursday, November 2nd. The stock was bought at an average price of $2.59 per share, for a total transaction of $65,527.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Dayton Misfeldt acquired 400,000 shares of Sunesis Pharmaceuticals stock in a transaction on Friday, October 27th. The stock was purchased at an average price of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. Insiders acquired a total of 506,800 shares of company stock valued at $1,091,282 in the last quarter. Corporate insiders own 10.21% of the company’s stock.
Several hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN raised its holdings in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 18,254 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals in the 2nd quarter worth approximately $208,000. Vanguard Group Inc. raised its holdings in shares of Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 23,819 shares in the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in shares of Sunesis Pharmaceuticals in the 2nd quarter worth approximately $5,400,000. Institutional investors own 38.21% of the company’s stock.
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up $0.24 during trading hours on Wednesday, reaching $4.25. The company had a trading volume of 138,920 shares, compared to its average volume of 227,304. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $4.45. The company has a market cap of $145.56, a P/E ratio of -2.43 and a beta of 1.53. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same quarter in the previous year, the company posted ($0.62) earnings per share. research analysts predict that Sunesis Pharmaceuticals will post -1.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Sunesis Pharmaceuticals, Inc. (SNSS) Receives $4.16 Consensus Price Target from Brokerages” was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/13/sunesis-pharmaceuticals-inc-snss-receives-4-16-consensus-price-target-from-brokerages.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.